8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02074410 (ClinicalTrials.gov) | January 2014 | 21/2/2014 | Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease | Huntington's Disease | Drug: OMS643762;Drug: Placebo | Omeros Corporation | NULL | Terminated | 18 Years | 65 Years | All | 22 | Phase 2 | United States |